Hikma Pharmaceuticals PLC Annual Report 2014 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS continued 26.
OTHER CURRENT LIABILITIES As at 31 December 2014 2013 $m $m Deferred revenue 46 47 Return and free goods provision 35 29 Other provisions 28 24 109 100 27.
LONG-TERM FINANCIAL DEBTS As at 31 December 2014 2013 $m $m Total loans 209 323 Less: current portion of loans Note 23 64 60 Long-term financial loans 145 263 Breakdown by maturity: Within one year 64 60 In the second year 65 61 In the third year 51 60 In the fourth year 13 51 In the fifth year 9 76 Thereafter 7 15 209 323 Breakdown by currency: US Dollar 173 280 Euro 6 10 Jordanian Dinar 4 5 Algerian Dinar 13 21 Egyptian Pound 8 5 Tunisian Dinar 5 2 209 323 The loans are held at amortised cost.
Long-term loans amounting to $12 million 2013: $14 million are secured.
Included in the table above are the following major arrangements entered into by the Group: a A seven-year syndicated term loan of $180 million which was entered into on 27 September 2011.
The loan has an outstanding balance atyear end of $64 million with a fair value of $63 million, of which $22 million is due in one year.
Quarterly equal repayments of $6 million commenced on 27 March 2013 18 months after the date of the agreement.
During 2014, a voluntary prepayment of $70 million was made.
The loan has been used to finance the Promopharm acquisition and the Groups general capital expenditure.
b A nine-year $110 million loan from the International Finance Corporation IFC was entered into on 19 December 2011.
The loan has an outstanding balance of $49 million at year end with a fair value of $48 million and a $50 million unused available limit.
Quarterly equal repayments for the term loan commenced on 15 November 2013 and will continue until 15 August 2020.
The loan has been used tofinance acquisitions in the MENA region and MENAs capital expenditure.
